Development of acute lymphoblastic leukemia following hemophagocytic lymphohistiocytosis: is it secondary leukemia?
Suzuki
T
T
Mugishima
H
H
Yamada
A
A
Nagata
T
T
Shichino
H
H
Chin
M
M
Imashuku
S
S
Harada
K
K
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D002675:Child, Preschool; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced / Q000209:etiology*
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003907:Dexamethasone